
Opinion|Videos|March 13, 2025
Clinical Perspectives for the Treatment of R/M NPC
Author(s)Lori J. Wirth, MD
A panelist discusses how the integration of immunotherapy into recurrent/metastatic (R/M) nasopharyngeal carcinoma (NPC) treatment requires careful patient monitoring for immune-related adverse events, strategic sequencing with other modalities, consideration of biomarker-guided approaches, and awareness of emerging combination strategies that may further improve outcomes, while ongoing research into novel immunotherapeutic agents, maintenance strategies, and treatment de-escalation protocols aims to optimize efficacy while minimizing toxicity in the evolving landscape of NPC management.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What clinical pearls and future directions can you share regarding the use of systemic immunotherapy for R/M NPC?
Advertisement
Related to this article

As LLMs expand access to cancer information, Prakash Peddi, MD, encourages patients to use available resources to better understand their disease and treatment options.

The phase 3 DasaHIT trial found that weekend dasatinib breaks maintained CML responses in first-line patients, with fewer effusions in exploratory analyses.

During a live event, Robert Orlowski, MD, PhD, and participants discussed selinexor combinations, dosing, and nausea prevention for an older patient with late relapsed multiple myeloma who declines CAR T.

Sac-TMT improved OS vs physician’s choice in pretreated gastroesophageal adenocarcinoma in the phase 3 TroFuse-015 trial; PFS was not improved.

Updated RMC-GI-102 data show 60.7% ORR and 12.8-month median PFS with daraxonrasib plus GnP in first-line metastatic PDAC.

Modern Hodgkin lymphoma treatment is tied to a 25% drop in solid second cancers, but breast and lung cancer risks persist for decades.

ESMO data show the phase 3 INTerpath-001 trial of intismeran autogene plus pembrolizumab improved recurrence-free survival in resected stage IIB to IV melanoma.
Advertisement
Advertisement
Trending on Targeted Onc
1
Daraxonrasib Plus Chemo Yields Durable Response in First-Line PDAC
2
ETHAN Trial: Rethinking Endocrine Therapy for Men's Breast Cancer
3
Taking Weekends Off Dasatinib Maintains Responses in First-Line CML
4
Contrasting Myeloma Therapies for Late Relapse in Patient Declining CAR T
5

